INT60554

From wiki-pain
Revision as of 17:47, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 1993
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 30
Total Number 33
Disease Relevance 7.99
Pain Relevance 3.02

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (Coq10a) cellular_component (Coq10a) biological_process (Coq10a)
Anatomy Link Frequency
NG108-15 1
brains 1
PSP 1
T lymphocytes 1
Coq10a (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 6 100.00 Very High Very High Very High
depression 3 98.84 Very High Very High Very High
opioid receptor 10 98.04 Very High Very High Very High
Calcium channel 4 97.28 Very High Very High Very High
projection neuron 3 96.80 Very High Very High Very High
opiate 2 95.92 Very High Very High Very High
Substantia nigra 32 94.92 High High
narcan 2 94.40 High High
fibrosis 20 92.96 High High
Opioid 19 92.00 High High
Disease Link Frequency Relevance Heat
Supranuclear Palsy 18 100.00 Very High Very High Very High
Vibrio Infection 45 99.84 Very High Very High Very High
Depression 3 98.84 Very High Very High Very High
Adhesions 20 98.40 Very High Very High Very High
Disease 244 98.36 Very High Very High Very High
Targeted Disruption 50 97.84 Very High Very High Very High
Alzheimer's Dementia 134 96.88 Very High Very High Very High
Apoptosis 87 96.20 Very High Very High Very High
Neuroblastoma 24 95.48 Very High Very High Very High
Death 135 94.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Clinical assessments using UPDRS III, Hoehn and Yahr stage, MMSE, and Montgomery Asberg Depression Scale showed no change.91 Currently a phase III trial of CoQ10 in PSP patients is recruiting, with a goal of 60 patients undergoing treatment with CoQ10 for one year (NCT00382824).


CoQ10 Binding (recruiting) of in PSP associated with depression and supranuclear palsy
1) Confidence 0.40 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 1.06 Pain Relevance 0.05
Taking advantage of barely detectable quantities of GM1 expressed in NECs (Yanagisawa et al., 2006a), we evaluated the incorporation of GM1 into the NECs by staining with Ctxb, a probe recognizing GM1 and other related gangliosides.
GM1 Binding (recognizing) of
2) Confidence 0.39 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.06 Pain Relevance 0
Our previous study using surface plasmon resonance and a liposome capture method showed that GM1 directly bound to A?
GM1 Binding (bound) of
3) Confidence 0.39 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.53 Pain Relevance 0.03
T lymphocytes, isolated from beta-endorphin-treated donors, and then depleted with anti-asialo GM1 antiserum and complement failed to demonstrate the detrimental effects of beta-endorphin.
GM1 Binding (depleted) of in T lymphocytes
4) Confidence 0.36 Published 1993 Journal J. Neuroimmunol. Section Abstract Doc Link 8505409 Disease Relevance 0.18 Pain Relevance 0.18
-(1–40) strongly interacts with GM1 only in the presence of cholesterol and sphingomyelin, components of cell surface microdomains, as reported by Kakio et al. (2001); the interaction between GM1 and FITC-A?
GM1 Binding (interaction) of
5) Confidence 0.35 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.06 Pain Relevance 0
Then, we analysed the physical interaction between GM1 and FITC-A?
GM1 Spec (analysed) Binding (interaction) of
6) Confidence 0.35 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.06 Pain Relevance 0
First, we confirmed the efficiency of the assay by detecting the interaction between GM1 and the well-known ligand, Ctxb.
GM1 Binding (interaction) of
7) Confidence 0.35 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.12 Pain Relevance 0
Bicelles containing GM1 were found to interact strongly with leucine enkephalin, whereas a somewhat weaker interaction was observed in the case of bicelles without GM1.
GM1 Binding (interaction) of associated with enkephalin
8) Confidence 0.32 Published 2008 Journal Langmuir Section Abstract Doc Link 18412380 Disease Relevance 0 Pain Relevance 0.80
Coenzyme Q10 has also been found to exert effects on ?
Coenzyme Q10 Binding (found) of
9) Confidence 0.31 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 1.67 Pain Relevance 0.05
Moreover, an assay of NADH to cytochrome-c reductase activity showed a significant increase in the patients treated with 1,200 mg CoQ10.78
CoQ10 Binding (1,200) of
10) Confidence 0.31 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.11 Pain Relevance 0
Thus we confirmed the physical interaction between GM1 and A?
GM1 Binding (interaction) of
11) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.24 Pain Relevance 0
As well, in NECs treated with GM1 and/or A?
GM1 Binding (/) of
12) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.62 Pain Relevance 0.05
GM1 binding assay
GM1 Binding (binding) of
13) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.07 Pain Relevance 0
The NECs treated with GM1 and/or A?
GM1 Binding (/) of
14) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.08 Pain Relevance 0.08
As shown in Figure 8(A), this assay could dose-dependently detect binding of Ctxb to GM1 immobilized on 96-well plates.
GM1 Binding (binding) of
15) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.11 Pain Relevance 0
In NECs treated with GM1 and/or A?
GM1 Binding (/) of
16) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0 Pain Relevance 0
In NSCs treated with GM1 and/or A?
GM1 Binding (/) of
17) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.10 Pain Relevance 0.03
Physical interaction between GM1 and A?
GM1 Binding (interaction) of
18) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.07 Pain Relevance 0
These results indicate that GM1 and 10 ?
GM1 Binding (indicate) of
19) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.14 Pain Relevance 0
It was confirmed that a number of NECs treated with GM1 and A?
GM1 Binding (treated) of
20) Confidence 0.30 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.63 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox